These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20382692)

  • 41. [PTH and bone metabolism in chronic dialysis patients].
    Fukagawa M; Kazama J; Shigematsu T
    Rinsho Byori; 2001 Mar; 49(3):236-8. PubMed ID: 11307321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH.
    Coen G; Ballanti P; Bonucci E; Calabria S; Costantini S; Ferrannini M; Giustini M; Giordano R; Nicolai G; Manni M; Sardella D; Taggi F
    Nephron; 2002 May; 91(1):103-11. PubMed ID: 12021526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vitamin D compounds for people with chronic kidney disease requiring dialysis.
    Palmer SC; McGregor DO; Craig JC; Elder G; Macaskill P; Strippoli GF
    Cochrane Database Syst Rev; 2009 Oct; (4):CD005633. PubMed ID: 19821349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Parathyroid hormone and large related C-terminal fragments increase at different rates with worsening of renal function in chronic kidney disease patients. A possible indicator of bone turnover status?
    Donadio C; Ardini M; Lucchesi A; Donadio E; Cantor T
    Clin Nephrol; 2007 Mar; 67(3):131-9. PubMed ID: 17390737
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response of the parathyroid gland to infusion of human parathyroid hormone-(1-34) [PTH-(1-34)]: demonstration of suppression of endogenous secretion using immunoradiometric intact PTH-(1-84) assay.
    Cosman F; Shen V; Herrington B; Lindsay R
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1345-51. PubMed ID: 1955517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hysteresis of the parathyroid hormone response to hypocalcemia in hemodialysis patients with low turnover aluminum bone disease.
    Felsenfeld AJ; Ross D; Rodriguez M
    J Am Soc Nephrol; 1991 Dec; 2(6):1136-43. PubMed ID: 1777594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients.
    Monier-Faugere MC; Geng Z; Mawad H; Friedler RM; Gao P; Cantor TL; Malluche HH
    Kidney Int; 2001 Oct; 60(4):1460-8. PubMed ID: 11576360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
    Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
    J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inverse correlation between serum magnesium and parathyroid hormone in peritoneal dialysis patients: a contributing factor to adynamic bone disease?
    Wei M; Esbaei K; Bargman JM; Oreopoulos DG
    Int Urol Nephrol; 2006; 38(2):317-22. PubMed ID: 16868704
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.
    Isakova T; Gutierrez O; Shah A; Castaldo L; Holmes J; Lee H; Wolf M
    J Am Soc Nephrol; 2008 Mar; 19(3):615-23. PubMed ID: 18216315
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
    J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Maintenance of normocalcemia by continuous infusion of the synthetic bovine parathyroid hormone (1-34) in parathyroidectomized rats.
    Ibrahim MM; Forte LR; Thomas ML
    Calcif Tissue Int; 1982; 34(6):553-7. PubMed ID: 6819076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients.
    Lorenzo V; Martín M; Rufino M; Jiménez A; Malo AM; Sanchez E; Hernández D; Rodríguez M; Torres A
    Am J Kidney Dis; 2001 Jun; 37(6):1260-6. PubMed ID: 11382697
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A lower proportion of circulating active parathyroid hormone in peritoneal dialysis does not allow the pth inter-method adjustment proposed for haemodialysis.
    González-Casaus ML; González-Parra E; Sánchez-González C; Albalate M; de la Piedra-Gordo C; Fernández E; Torregrosa V; Rodríguez M; Lorenzo V
    Nefrologia; 2014 May; 34(3):330-40. PubMed ID: 24798561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients.
    Navarro JF; Mora C; Jiménez A; Torres A; Macía M; García J
    Am J Kidney Dis; 1999 Jul; 34(1):43-8. PubMed ID: 10401014
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bone mineral disturbances in patients with chronic kidney disease stage 5 not yet on dialysis.
    Marn Pernat A; Zrimšek M
    Clin Nephrol; 2017 Supplement 1; 88(13):39-43. PubMed ID: 28619127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.